SCHEMBL3534134

SCHEMBL3534134

c1ccc2c(-c3cccc4cncn34)coc2c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 2/20 0.61
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
TBXAS1 P24557 10/20 0.34
CYP11B1 P15538 1/20 0.33
GSK3B P49841 3/20 0.32
GRK2 P25098 1/20 0.32
CDK2 P24941 1/20 0.32
NISCH Q9Y2I1 1/20 0.32
CCNC P24863 1/20 0.32
CDK8 P49336 1/20 0.32
IKBKE Q14164 1/20 0.32
TBK1 Q9UHD2 1/20 0.32
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
PTGIS Q16647 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3534828 0.99 CYP11B2 (0.59) CYP11B2CHRM2CHRM4CHRM5CHRM1
Hydrochloric Acid SCHEMBL3539978 0.75 CYP11B2 (0.97) CYP11B2TBXAS1CYP11B1
SCHEMBL3540598 0.71 CYP11B2 (0.65) CYP11B2TBXAS1GSK3BCDK8PTGS1
Hydrochloric Acid SCHEMBL3535788 0.70 CYP11B2 (0.63) CYP11B2TBXAS1GSK3BCDK8PTGS1
SCHEMBL21323991 0.70 CYP11B2 (0.55) CYP11B2TBXAS1
SCHEMBL2490828 0.68 CHRM2 (0.50) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL9261340 0.68 CYP11B2 (0.60) CYP11B2TBXAS1
SCHEMBL3536508 0.67 CYP11B2 (0.55) CYP11B2TBXAS1CYP11B1GSK3BCDK8
Hydrochloric Acid SCHEMBL3537661 0.66 CYP11B2 (0.54) CYP11B2TBXAS1CYP11B1GSK3BCDK8
SCHEMBL812221 0.63 PRKCZ (0.40) CYP11B2CHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713991-B2 Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases NOVARTIS AG (CH) 2010-05-11 US claimed
US-20070197582-A1 IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES NOVARTIS AG (CH) 2007-08-23 US claimed
US-7223866-B2 Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases NOVARTIS AG (CH) 2007-05-29 US claimed
US-20060058342-A1 Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases NOVARTIS AG (CH) 2006-03-16 US claimed
US-7713991-B2 Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases NOVARTIS AG (CH) 2010-05-11 US disclosed
US-7713991-B2 Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases NOVARTIS AG (CH) 2010-05-11 US disclosed
US-7713991-B2 Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases NOVARTIS AG (CH) 2010-05-11 US disclosed
EP-1565463-B1 IMIDAZO[1,5A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES NOVARTIS AG (CH) 2008-06-11 EP disclosed
US-20070197582-A1 IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES NOVARTIS AG (CH) 2007-08-23 US disclosed
US-20070197582-A1 IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES NOVARTIS AG (CH) 2007-08-23 US disclosed
US-20070197582-A1 IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES NOVARTIS AG (CH) 2007-08-23 US disclosed
US-7223866-B2 Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases NOVARTIS AG (CH) 2007-05-29 US disclosed
US-7223866-B2 Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases NOVARTIS AG (CH) 2007-05-29 US disclosed
US-7223866-B2 Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases NOVARTIS AG (CH) 2007-05-29 US disclosed
US-20060058342-A1 Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases NOVARTIS AG (CH) 2006-03-16 US disclosed
EP-1565463-A1 IMIDAZO[1,5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES Novartis AG (CH) 2005-08-24 EP disclosed
WO-2004046145-A1 IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES NOVARTIS AG (CH) 2004-06-03 WO disclosed
WO-2004046145-A1 IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES NOVARTIS AG (CH) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058342-A1 Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases CYP11B1, CYP17A1, CYP27A1 CYP11B2 8/4885CHRM2 1867/4885CHRM4 2491/4885
US-20070197582-A1 IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES CYP11B1, CYP27A1, CYP17A1 CYP11B2 7/4885CHRM2 1704/4885CHRM4 2306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.